Tempus AI to Acquire Personalis for $1.5bn in Oncology Deal

Tempus AI will acquire Personalis for $1.5 billion in a stock deal set to close by early 2027, paying $16.25 per share—representing a 6% premium on Personalis' recent close of $15.39. Following the announcement on July 20, Tempus shares fell by 7.74%, closing at $48.41, while Personalis stock dropped 13.2% to $13.34. Despite a reported preliminary Q2 revenue of $22.4 million from Personalis and a 33% increase in MRD test volumes, concerns about profitability persist. This acquisition positions Tempus to enhance its oncology services, particularly in minimal residual disease testing, which is increasingly important for cancer patient monitoring.